Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929292 | 0.94 | MAPK14 (0.35) | ALDH1A1NPSR1CA2MAPK14HTR1A | |
| SCHEMBL717265 | 0.87 | CA2 (0.38) | ALDH1A1NPSR1CA2MAPK14 | |
| SCHEMBL12943469 | 0.81 | ALDH1A1 (0.34) | ALDH1A1NPSR1CA2MAPK14HTR1A | |
| SCHEMBL711059 | 0.78 | APP (0.39) | ALDH1A1 | |
| SCHEMBL928936 | 0.74 | ALDH1A1 (0.35) | ALDH1A1NPSR1CA2HTR1AADRA1D | |
| SCHEMBL2987015 | 0.71 | CYP2C9 (0.40) | CA2 | |
| SCHEMBL8500697 | 0.71 | GPR84 (0.33) | — | |
| SCHEMBL13552003 | 0.70 | ALDH1A1 (0.38) | ALDH1A1NPSR1CA2MAPK14HTR1A | |
| SCHEMBL2983769 | 0.70 | MAPT (0.36) | ALDH1A1NPSR1 | |
| SCHEMBL3891060 | 0.70 | ALDH1A1 (0.32) | ALDH1A1HTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-2065379-A1 | BENZIMIDAZOLE COMPOUND HAVING GASTRIC ACID SECRETION INHIBITORY ACTIVITY | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
| EP-2065379-A1 | BENZIMIDAZOLE COMPOUND HAVING GASTRIC ACID SECRETION INHIBITORY ACTIVITY | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | ALDH1A1 180/4885NPSR1 1979/4885CA2 108/4885 |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | ALDH1A1 180/4885NPSR1 1979/4885CA2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.